Merrimack Pharmaceuticals Stock Current Ratio

Merrimack Pharmaceuticals fundamentals help investors to digest information that contributes to Merrimack Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Merrimack Stock. The fundamental analysis module provides a way to measure Merrimack Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Merrimack Pharmaceuticals stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Merrimack Pharmaceuticals Company Current Ratio Analysis

Merrimack Pharmaceuticals' Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.

Current Ratio

 = 

Current Asset

Current Liabilities

More About Current Ratio | All Equity Analysis

Current Merrimack Pharmaceuticals Current Ratio

    
  31.85 X  
Most of Merrimack Pharmaceuticals' fundamental indicators, such as Current Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Merrimack Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
Competition

In accordance with the recently published financial statements, Merrimack Pharmaceuticals has a Current Ratio of 31.85 times. This is much higher than that of the Biotechnology sector and notably higher than that of the Health Care industry. The current ratio for all United States stocks is notably lower than that of the firm.

Merrimack Current Ratio Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Merrimack Pharmaceuticals' direct or indirect competition against its Current Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Merrimack Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Merrimack Pharmaceuticals by comparing valuation metrics of similar companies.
Merrimack Pharmaceuticals is currently under evaluation in current ratio category among its peers.

Merrimack Fundamentals

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.

Other Consideration for investing in Merrimack Stock

If you are still planning to invest in Merrimack Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Merrimack Pharmaceuticals' history and understand the potential risks before investing.
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Insider Screener
Find insiders across different sectors to evaluate their impact on performance